Antidiabetic and hypolipidemic potential of DRF 2519 - A dual activator of PPAR-α and PPAR-γ

European Journal of Pharmacology

Volumn 491, Issue 2-3, 2004, Pages 195-206

  Chakrabarti, Ranjan ^a   Misra, Parimal ^a   Vikramadithyan, Reeba K ^a   Premkumar, Mamnoor ^a   Hiriyan, Jagadheshan ^a   Datla, Srinivas R ^a   Damarla, Ravi K B ^a   Suresh, Juluri ^a   Rajagopalan, Ramanujam ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

Author keywords

Antidiabetic; Hypolipidemic; Insulin sensitizer; Peroxisome proliferators activated receptor (PPAR)

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACYL COENZYME A OXIDASE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; DRF 2519; FATTY ACID; FENOFIBRATE; INSULIN; LIPOPROTEIN LIPASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; ENZYME INDUCTION; FATTY ACID BLOOD LEVEL; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ANALYSIS; LIPID DIET; LIPOGENESIS; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; RAT STRAIN; SMOOTH MUSCLE RELAXATION; TRANSACTIVATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; AORTA, THORACIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; PPAR ALPHA; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RATS, ZUCKER; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 2342644036     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.03.034     Document Type: Article

References (47)

1. Ali S., Igwe R., Walsh M., Sowers J. Troglitazone and vascular reactivity: role of glucose and calcium. Metabolism. 48:1999;125-130
2. Assimacopoulos-Jeannet F., Jeanrenaud B. The hormonal and metabolic basis of experimental obesity. Clin. Endocrinol. Metab. 5:1976;337-365
3. Balfour J.A.B., Plosker G.L. Rosiglitazone. Drugs. 57:1999;921-930
4. Baron A., Brechtel G., Johnson A., Hardin D. Skeletal muscle blood flow: a possible link between insulin resistance and blood pressure hypertension. Hypertension. 21:1993;129-135
5. Basu-Modak S., Braissant O., Escher P., Desvergne B., Honegger P., Wahli W. Peroxisime proliferator activated receptor beta regulates acyl CoA synthetase 2 in reaggregated rat brain cell cultures. J. Biol. Chem. 274:1999;35881-35888
6. Boden G. Mechanism of fatty acid induced inhibition of glucose uptake. J. Clin. Invest. 93:1994;2438-2446
7. Cantello B.C.C., Cawthorne M.A., Cottam G.P., Duff P.T., Haigh D., Hindley R.M., Lister C.A., Smith S.A., Thurlby P.L. [[Omega-(heterocyclyamino) alkoxy]benzyl]-2, 4-thiazolidonediones as potent antihyperglycemic agents. J. Med. Chem. 37(23):1994;3977-3985
8. Defronzo R.A., Bondonna R.C., Ferranini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care. 15:1992;318-367
9. Etegen G.J., Oldham B.A., Johnson W.T., Broderic C.L., Montros eC.R., Brozinick J.T., Paterniti J.R., Ogilvie K.M., Liu S., Kaufman R.F. A tailored therapy for metabolic disorder. Diabetes. 51:2002;1083-1087
10. 2 is a ligand for the adipocyte determination factor PPAR-γ Cell. 83:1995;803-812
11. Forman B.M., Chon J., Evans R.M Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for peroxisome proliferator activated receptor α and δ Proc. Natl. Acad. Sci. U. S. A. 94:1997;4312-4317
12. Genuth S.M., Przybylski R.J., Rosenberg D.M. Insulin resistance in genetically obese, hyperglycemic mice. Endocrinology. 88:1971;1230-1238
13. Gliemann J., Osterland K., Vinten J., Gammeltoft S. A procedure for measurement of distribution spaces in isolated fat cells. Biochim. Biophys. Acta. 286:1972;1-9
14. Goldberg I.J. Lipoprotein lipase and lipolysis. J. Lipid Res. 37:1996;693-707
15. Goodpaster B.H., Kelly D.E. Role of muscle in triglyceride metabolism. Curr. Opin. Lipidol. 9:1998;231-236
16. Grundy S.M., Mok H.Y., Zech L., Steinberg D., Berman M. Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. J. Clin. Invest. 63:1979;1274-1283
17. Guerre-Milo M., Gervois P., Raspe E., Madsen L., Poulain P., Derudas B., Herbert J.M., Winegar D.A., Willson T.M., Fruchart J.C., Berge R.K., Staels B. Peroxisome proliferators activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275:2000;16638-16642
18. Haffner S., Mitchell B.D., Valdez R.A., Hazuda H.P., Morales P.A., Stern M.P. Eight year incidence of hypertension in Mexican-Indians and non-Hispanic whites. The San Antonio heart study. Am. J. Hypertens. 5:1992;147-153
19. Herberg L., Coleman D.L. Laboratory animals exhibiting obesity and diabetes syndromes. Metabolism. 26:1997;59-99
20. Howard B.V. Lipoprotein metabolism in diabetes mellitus. J. Lipid Res. 28:1987;613-628
21. Hunt C.E. Andrews E.J., Ward B.C., Altman N.H. In Spontaneous Animal Models of Human Disease. vol. 2:1979;76 Academic Press, New York. Chap. 185
22. Huttunen J., Mannien V., Mantarri M., Koskinen P., Romo M., Tenkanen I., Heinonen O., Frick M. The Helisinki heart study: central findings and clinical implications. Ann. Med. 23:1991;155-159
23. Iverius P.H., Lindqvist A.M.O. Preparation, characterisation and measurement of lipoprotein lipase. Methods in Enzymology. 129:1986;691-704
24. Lehman J.M., Moore L.B., Oliver-Smith T.A., Wilkinson W.O., Wilson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator activator receptor gamma. J. Biol. Chem. 270:1995;12953-12956
25. Lohray V.B., Lohray B.B., Paraselli B.B., Ramanujam R., Chakrabarti R. New thiazolidinedione and oxazolidinedione derivatives - useful for the treatment of e.g., hyperlipidemia, diabetes, hypertension, renal diseases and eating orders. P.C.T. 1991;7-60. Publication No. WO 9845291-A1
26. Loviscach M., Henry R.R. Clinical significance of peroxisome proliferator activated receptors in health and disease. Medscape Diabet. Endocrinol. 1999;1-14
27. Martin G., Schoonjans K., Lefebvre A.M., Staels B., Auwrex J. Coordinate regulation of the expression of the fatty acid transport protein and acyl CoA synthetase genes by PPAR-α and PPAR-γ activators. J. Biol. Chem. 272:1997;28210-28217
28. Murami K., Tobe K., Ide T., Mochizuki T., Ohashi M., Akanuma Y., Yazaki Y., Kadowaki T. A novel insulin sensitizer acta as a coligand for peroxisome proliferator activated receptor-α (PPAR-α) and PPAR-γ Diabetes. 47:1996;1841-1847
29. Oakes N.D., Camilleri S., Furler S.M., Chisholm D.J., Kraegen E.W. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilisation and tissue lipid availability in the rat. Metabolism. 46:1997;935-942
30. Perry C., Petrie J.R. Insulin sensitizing agents. Emerg. Drugs. 3:1998;247-260
31. Petit D., Bonnefis M.T., Rey C. Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats. Atherosclerosis. 74:1988;215-225
32. Randle P.J., Garland P.B., Hales C.N., Newsholme E.A. The glucose fatty acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1:1963;785-789
33. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1988;1495-1507
34. Reaven G.M., Chen Y.D. Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes Metab. Rev. 4:1998;639-652
35. Reaven G.M., Chen Y.D., Jeppesen J., Maheux P., Krauss R.M. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J. Clin. Invest. 92:1993;141-146
36. Rubins H.B., Robins S.J., Collins D. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. Veterans Affairs High Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341:1999;410-418
37. Schoonjans K., Peindo-Osurbe J., Lefbvre A.M., Heyman R.A., Briggs M., Deebs S., Staels B., Auwrex J. PPAR-α and PPAR-γ activators direct a distinct tissue specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15:1996;5336-5348
38. Schoonjans K., Staels B., Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta. 1302(2):1996;93-109
39. Shinkai H. The chemical structure and pharmacological properties of a novel isoxazolidinedione insulin sensitizer, JTT-501. Nippon Rinsho. 59:2001;2207-2210
40. Shinozaki K., Suzuki M., Ikebuchi M., Takai H., Hara Y., Tsushima M., Harano Y. Insulin resistance associated with compensatory hyperinsulinemia as an independent risk factor for vasospastic angina. Circulation. 92:1995;1749-1757
41. Shinozaki K., Suzuki M., Ikebuchi M., Hara Y., Harano Y. Demonstration of insulin resistance in coronary artery disease documented with angiography. Diabetes Care. 19:1996;1-7
42. Stales B., Auwrex J. Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones. Curr. Pharm. Des. 3:1997;1-14
43. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98:1998;2088-2093
44. Steinberg H., Chaker H., Leaming R., Johnson A., Berchtel G., Baron A. Obesity/insulin resistance is associated with endothelial dysfunction: implication for the syndrome for insulin resistance. J. Clin. Invest. 97:1996;2601-2610
45. Taskinen M.R. Insulin resistance and lipoprotein metabolism. Curr. Opin. Lipidol. 6:1995;153-160
46. United Kingdom Prospective Diabetes Study Group Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS-33). Lancet. 352:1998;837-853
47. Wilson T.M., Brown P.J., Sternbach D.D., Henke B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43:2000;527-550